[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pancreatic-cancer-stage-ii\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pancreatic-cancer-stage-ii":35},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,58],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":39,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":57},"100545979","pancreatic-cancer-detection-consortium-100545979",false,"NCT06388967","Pancreatic Cancer Detection Consortium","Early Detection of Pancreatic Cancer: Prospective Study","PCDC","Inclusion Criteria:\n\n* Histological diagnosis of pancreatic ductal adenocarcinoma, stages I-IV (TNM classification, 8th edition)\n* Received standard diagnostic and staging procedures as per local guidelines, and at least one sample was drawn before receiving any curative-intent treatment.\n* Imaging- or endoscopy-based proof of lack of pancreatic ductal adenocarcinoma at the time of sampling (Non-disease controls)\n\nExclusion Criteria:\n\n* Lack of written informed consent.",true,"ALL","18 Years",{"count":21,"type":22},2000,"ESTIMATED","OBSERVATIONAL","This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.",[26,27,28,29,30,31,32,33,34,35,36,37,38],"Pancreatic Cancer","Pancreatic Carcinoma","Pancreatic Adenocarcinoma","Pancreatic Ductal Adenocarcinoma","Pancreatic Neoplasms","Pancreatic Cancer Stage I","Pancreatic Cancer Stage","Pancreatic Cancer Resectable","Pancreatic Cancer Stage 0","Pancreatic Cancer Stage II","Pancreatic Cancer Stage III","Pancreatic Cancer, Adult","Pancreatic Cancer Non-resectable",[40,41,42,43,44],"Micro RNA","Exosome","Cell free","Early detection","Screening","RECRUITING","2025-12-17",{"date":48,"type":49},"2025-12-19","ACTUAL",{"date":51,"type":49},"2023-03-15",{"date":53,"type":22},"2026-06-18",{"name":55,"class":56},"City of Hope Medical Center","OTHER",11,{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":18,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":70,"conditions":71,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":4},"100582852","neoadjuvant-chemotherapy-for-elderly-with-pancreatic-head-cancer-100582852","NCT06868693","Neoadjuvant Chemotherapy for Elderly with Pancreatic Head Cancer","Pancreatic Cancer of the Head: Effect of Neoadjuvant Chemotherapy in Elderly People - a Multicenter Observational Study","PEACE","Inclusion Criteria\n\n* Patients aged ≥ 70 years\n* Patients with resectable or BR PDAC who underwent curative treatment (NAT followed by surgery and upfront surgery)\n* Patients with Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) \\> 2\n* Patients able to provide informed consent, whenever possible\n\nExclusion Criteria\n\n* Patients not meeting the inclusion criteria.\n* Pancreatic cancer of pancreatic body and tail.\n* Patients with metastatic disease.\n* Patients with locally advanced or metastatic pancreatic cancer","70 Years","100 Years",{"count":69,"type":22},240,"The goal of this observational retrospective cohort study is to evaluate the efficacy and safety of neoadjuvant chemotherapy (NAT) in elderly patients with resectable or borderline resectable (BR) pancreatic ductal adenocarcinoma (PDAC). The study includes patients aged ≥70 years who have undergone NAT followed by surgery or upfront surgery.\n\nThe main questions it aims to answer are:\n\nDoes NAT improve overall survival (OS) and progression-free survival (PFS) in elderly patients compared to upfront surgery? What is the impact of NAT on R0 resection rates, conversion rates in BR tumors, and the need for vascular resection? How does the toxicity profile of different NAT regimens affect treatment outcomes and patient tolerability? Researchers will compare NAT followed by surgery vs. upfront surgery to determine differences in oncologic outcomes and postoperative complications.\n\nParticipants will:\n\nBe retrospectively identified from hospital records. Be classified based on treatment received (NAT vs. upfront surgery). Undergo data collection on tumor characteristics, treatment regimens, surgical details, and survival outcomes.\n\nThis study aims to refine patient selection criteria for NAT in elderly patients, guiding personalized treatment strategies to optimize survival and quality of life.",[33,35,72,73,74],"Neoadjuvant Therapy","Elderly","Borderline Pancreatic Inoperable Cancer","NOT_YET_RECRUITING","2025-03-08",{"date":78,"type":49},"2025-03-11",{"date":80,"type":22},"2026-01-01",{"date":82,"type":22},"2026-12",{"name":84,"class":56},"Azienda Unita Sanitaria Locale di Piacenza"]